Follow the Eupraxia Pharmaceuticals Inc. stock price and the full insider trade history of the company, a listed issuer based in Canada. Shares are quoted on CA CA, under the authority of SEDI. Market capitalisation: €608.2m. The latest transaction was disclosed on 30 June 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Pott, Amy. Every trade is openly available.
29
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Eupraxia Pharmaceuticals Inc. Strong Buy (bullish), based on 3 analysts. Average price target: CA$16.33.
31Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
24,000 shares@ CA$8.63100.0% of flowRights Restricted Stock UnitTSXSEDI:4626134
25 of 29 declarations
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases and musculoskeletal disorders. It is listed on the XTSE market.